Biomind Labs Inc. (BMNDF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biomind Labs Inc. (BMNDF) trades at $0.1978 with AI Score 44/100 (Grade C). Biomind Labs Inc. is a biotechnology company focused on developing pharmaceutical drugs and nanotech delivery systems for psychiatric and neurological conditions. Market cap: $15.3M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BMNDF: BMNDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMNDF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BMNDF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Biomind Labs Inc. (BMNDF) Healthcare & Pipeline Overview
Biomind Labs Inc. is a biotech firm developing novel pharmaceutical drugs and nanotech delivery systems for psychiatric and neurological conditions, including depression and Alzheimer's. Its focus on Phase II clinical trials and preclinical drug candidates positions it within the competitive biotechnology landscape, targeting unmet needs in mental health.
What Is the Investment Thesis for BMNDF?
Biomind Labs Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful completion of its Phase II clinical trials for BMND01 and BMND08, targeting depression and Alzheimer's-related anxiety, respectively. Positive trial outcomes could serve as a significant catalyst, driving valuation growth. However, the company's small market capitalization of $15.3M and limited resources introduce substantial execution risk. The success of preclinical drug candidates, such as BMND02 for fibromyalgia and BMND03 for addictive disorders, represents longer-term growth potential. Investors should closely monitor clinical trial data, regulatory milestones, and the company's ability to secure funding to support ongoing research and development. The negative P/E ratio of -78.50 reflects the company's current lack of profitability, underscoring the speculative nature of this investment.
Based on FMP financials and quantitative analysis
BMNDF Key Highlights
- BMND01 is in Phase II clinical trials for the treatment of depression.
- BMND08 is in Phase II clinical trials for the treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment.
- The company is developing a pipeline of preclinical drug candidates targeting fibromyalgia, addictive disorders, chronic pain, inflammation, and major depressive disorder.
- Market capitalization of $15.3M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -78.50 reflects the company's current lack of profitability due to its focus on research and development.
Who Are BMNDF's Competitors?
BMNDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CAIHF Chia Tai Enterprises International Limited | $0.28 | +0.00% | $217M | 53 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.37 | +2.74% | $268M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMNDF's Key Strengths?
- Pipeline of drug candidates targeting unmet needs in mental health.
- Focus on innovative nanotech delivery systems.
- Two drug candidates in Phase II clinical trials.
- Experienced leadership team with expertise in drug development.
What Are BMNDF's Weaknesses?
- Limited financial resources and small market capitalization.
- High dependence on successful clinical trial outcomes.
- Early-stage development with significant regulatory hurdles.
- Limited commercialization experience.
What Could Drive BMNDF Stock Higher?
- Release of Phase II clinical trial data for BMND01 in depression treatment (expected in 2027).
- Release of Phase II clinical trial data for BMND08 in Alzheimer's-related anxiety treatment (expected in 2027).
- Advancement of preclinical drug candidates (BMND02, BMND03, BMND05, BMND06, BMND07) through preclinical studies.
- Potential for strategic partnerships with larger pharmaceutical companies or research institutions.
- Securing additional funding to support ongoing research and development activities.
What Are the Key Risks for BMNDF?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for BMND01 and BMND08.
- Regulatory setbacks and delays in obtaining approvals.
- Competition from established pharmaceutical companies with greater resources.
- Difficulty securing funding for ongoing research and development.
- Intellectual property disputes or challenges to patent protection.
What Are the Growth Opportunities for BMNDF?
- Expansion into New Therapeutic Areas: Biomind Labs has the opportunity to expand its pipeline beyond its current focus on depression and Alzheimer's-related anxiety. Developing treatments for other psychiatric and neurological conditions, such as PTSD, anxiety disorders, and Parkinson's disease, could significantly broaden the company's market reach. The market for neurological disorder treatments is projected to reach $158 billion by 2028, presenting a substantial growth opportunity for Biomind Labs. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Biomind Labs with access to additional funding, expertise, and resources. Collaborations can accelerate drug development timelines and increase the likelihood of successful commercialization. The global pharmaceutical market is driven by collaborations, with deals valued at billions of dollars annually. Timeline: Ongoing.
- Advancement of Nanotech Delivery Systems: Biomind Labs' focus on nanotech delivery systems offers a competitive advantage in enhancing drug efficacy and bioavailability. Further development and optimization of these delivery systems could lead to more effective treatments and improved patient outcomes. The nanomedicine market is expected to reach $393.7 billion by 2030, driven by advancements in drug delivery technologies. Timeline: Ongoing.
- Geographic Expansion: Expanding operations beyond Uruguay and targeting key markets in North America and Europe could drive revenue growth and increase market share. These regions have well-established healthcare systems and a high demand for innovative treatments. The North American pharmaceutical market is the largest globally, accounting for over 40% of worldwide sales. Timeline: 2027-2029.
- Regulatory Approvals and Commercialization: Obtaining regulatory approvals for BMND01 and BMND08 in major markets, such as the United States and Europe, would be a significant catalyst for growth. Successful commercialization of these drugs could generate substantial revenue streams and establish Biomind Labs as a key player in the mental health treatment market. The FDA approval process typically takes several years, but expedited pathways are available for breakthrough therapies. Timeline: 2028-2030.
What Opportunities Does BMNDF Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas and geographic markets.
- Advancement of preclinical drug candidates.
- Increasing demand for mental health treatments.
What Threats Does BMNDF Face?
- Competition from established pharmaceutical companies.
- Regulatory setbacks and clinical trial failures.
- Difficulty securing funding for ongoing research and development.
- Changing market dynamics and evolving treatment paradigms.
What Are BMNDF's Competitive Advantages?
- Proprietary drug formulations and nanotech delivery systems.
- Intellectual property protection through patents and trademarks.
- Clinical trial data demonstrating safety and efficacy.
- First-mover advantage in developing psychedelic-based therapies for specific conditions.
What Does BMNDF Do?
Biomind Labs Inc., headquartered in Canelones, Uruguay, is a biotechnology research and development company founded with the goal of creating innovative treatments for psychiatric and neurological conditions. The company specializes in developing novel pharmaceutical drugs and nanotech delivery systems to address a range of mental health disorders. Currently, Biomind Labs has two lead drug candidates in Phase II clinical trials: BMND01 for the treatment of depression and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate, for treating depression and anxiety in patients with Alzheimer's-type cognitive impairment. Beyond these clinical-stage assets, Biomind Labs is also advancing a pipeline of preclinical drug candidates targeting various conditions, including BMND02 for fibromyalgia, BMND03 for addictive disorders, BMND05 for chronic pain, BMND06 for inflammation, and BMND07 for major depressive disorder. The company's strategy involves leveraging nanotech delivery systems to enhance drug efficacy and bioavailability. With a small team of 5 employees, Biomind Labs is focused on research and development, aiming to bring innovative solutions to the market for underserved mental health conditions. The company operates primarily in the biotechnology sector, focusing on pharmaceutical drug development and nanotech applications within the healthcare industry.
What Products and Services Does BMNDF Offer?
- Develop novel pharmaceutical drugs for psychiatric conditions.
- Create nanotech delivery systems for enhanced drug efficacy.
- Conduct Phase II clinical trials for depression treatments (BMND01).
- Conduct Phase II clinical trials for Alzheimer's-related anxiety treatments (BMND08).
- Advance preclinical drug candidates for fibromyalgia, addictive disorders, chronic pain, inflammation, and major depressive disorder.
- Focus on research and development in the biotechnology sector.
- Target unmet needs in mental health treatment.
How Does BMNDF Make Money?
- Develop and patent novel pharmaceutical drugs and nanotech delivery systems.
- Conduct clinical trials to demonstrate the safety and efficacy of drug candidates.
- Seek regulatory approvals from agencies like the FDA and EMA.
- Commercialize approved drugs through partnerships or direct sales.
What Industry Does BMNDF Operate In?
Biomind Labs Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The company focuses on developing treatments for psychiatric and neurological conditions, aligning with the growing recognition of mental health as a critical area of unmet medical need. The market for depression and Alzheimer's disease treatments is substantial, with increasing demand for novel therapies. Biomind Labs competes with other biotechnology and pharmaceutical companies, including those developing psychedelic-based therapies. Success in this industry requires strong scientific expertise, effective clinical trial execution, and the ability to navigate complex regulatory pathways.
Who Are BMNDF's Key Customers?
- Patients suffering from psychiatric and neurological conditions.
- Healthcare providers who prescribe and administer treatments.
- Pharmaceutical companies that may license or acquire Biomind Labs' drug candidates.
- Research institutions and collaborators.
F-Score 1/9Financial Health
Biomind Labs Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BMNDF Valuation & Market Position
With a $15.3M market cap, Biomind Labs Inc. sits in the micro-cap segment of the market. Relative to its peer group, BMNDF's quantitative score of 44/100 is below the peer average of 70/100.
ROE 63%Key Financial Metrics
Return on equity for Biomind Labs Inc. stands at 62.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -9.6%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Biomind Labs Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Alejandro Antalich. BMNDF has traded publicly since 2021.
BMNDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Biomind's growth potential, indicating insiders believe the company is undervalued.
- Community sentiment has shifted positively, with discussions highlighting the innovative approaches Biomind is taking in the psychedelic therapy space.
- Increased media coverage has sparked interest, positioning Biomind as a key player in the emerging mental health treatment market.
- Recent partnerships and collaborations have enhanced Biomind's credibility and visibility, attracting more investor interest.
Bear Case
- Concerns over regulatory hurdles in the psychedelic industry could hinder Biomind's progress, creating uncertainty among investors.
- Recent social media discussions have revealed skepticism about the scalability of Biomind's products, with some questioning their market viability.
- Insider selling activity has raised red flags for some investors, potentially indicating a lack of confidence in the near-term outlook.
- Overall market sentiment towards biotech stocks has been cautious, affecting investor enthusiasm for companies like Biomind.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BMNDF Latest News
No recent news available for BMNDF.
BMNDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMNDF.
Price Targets
Wall Street price target analysis for BMNDF.
BMNDF MoonshotScore
What does this score mean?
The MoonshotScore rates BMNDF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alejandro Antalich
CEO
Alejandro Antalich serves as the CEO of Biomind Labs Inc. His background includes experience in managing small teams and overseeing research and development activities within the biotechnology sector. While specific details regarding his educational background and previous roles are not available, his leadership is focused on guiding Biomind Labs through its clinical trials and advancing its pipeline of drug candidates. He is responsible for strategic decision-making and securing funding for the company's operations.
Track Record: Under Alejandro Antalich's leadership, Biomind Labs has advanced two drug candidates, BMND01 and BMND08, into Phase II clinical trials. He has also overseen the development of a pipeline of preclinical drug candidates targeting various psychiatric and neurological conditions. His focus has been on securing funding and managing the company's research and development efforts. However, given the company's early stage and limited information available, a comprehensive assessment of his track record is challenging.
BMNDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and there are no minimum financial standards required for inclusion. This tier is often associated with higher risk and greater potential for fraud due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution when considering investments in OTC Other securities.
- OTC Tier: OTC Other
- Limited or no financial disclosure requirements.
- Higher potential for fraud and manipulation.
- Lack of regulatory oversight and transparency.
- Significant liquidity risk due to low trading volumes.
- Increased volatility and price swings.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Research any legal or regulatory issues involving the company.
- Consult with a qualified financial advisor before investing.
- Presence of a functional website and contact information.
- Listing of key management personnel.
- Publicly available press releases or announcements.
- Involvement in clinical trials and research activities.
- Focus on developing treatments for unmet medical needs.
What Investors Ask About Biomind Labs Inc. (BMNDF) — Healthcare
What does the AI Score mean for BMNDF?
BMNDF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Biomind Labs Inc. is a biotechnology company focused on developing pharmaceutical drugs and nanotech delivery systems for psychiatric and neurological conditions. The company's pipeline includes …
What does Biomind Labs Inc. do?
Biomind Labs Inc. is a biotechnology company focused on developing novel pharmaceutical drugs and nanotech delivery systems for psychiatric and neurological conditions. The company's primary focus is on advancing its pipeline of drug candidates, including BMND01 for depression and BMND08 for Alzheimer's-related anxiety, both currently in Phase II clinical trials.
What do analysts say about BMNDF stock?
As of March 17, 2026, there is no available analyst coverage or consensus rating for BMNDF stock. Given the company's small market capitalization of $15.3M and its listing on the OTC Other tier, it is unlikely that major brokerage firms or research institutions provide in-depth analysis.
What are the main risks for BMNDF?
Investing in BMNDF carries significant risks due to its early-stage development, limited financial resources, and listing on the OTC Other tier. Clinical trial failures for BMND01 and BMND08 would have a material adverse impact on the company's valuation. Regulatory setbacks and delays in obtaining approvals are also major concerns. Competition from established pharmaceutical companies with greater resources poses a threat.
What are the key factors to evaluate for BMNDF?
Biomind Labs Inc. (BMNDF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does BMNDF data refresh on this page?
BMNDF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BMNDF's recent stock price performance?
Biomind Labs Inc. (BMNDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of drug candidates targeting unmet needs in mental health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMNDF overvalued or undervalued right now?
Biomind Labs Inc. (BMNDF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BMNDF before investing?
Before investing in Biomind Labs Inc. (BMNDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.
- AI analysis pending.